Loop-mediated isothermal amplification coupled with a nanoparticle-based lateral biosensor for rapid, sensitive, and specific detection of Talaromyces marneffei

Introduction: Talaromyces marneffei (T.marneffei) is a pathogenic dimorphic fungus endemic in Southeast Asia and southern China. It can be found in the environment (soil and decaying wood) and may infect human hosts following the inhalation of spores. The disseminated infection of T.marneffei can be life-threatening without timely diagnosis and effective antifungal therapy.

Methods: Herein, we proposed a simple, rapid, sensitive and visual point-of-care detection method for detecting T.marneffei using loop-mediated isothermal amplification combined with a nanoparticle-based lateral flow biosensor (T.marneffei-LAMP-LFB). A set of six primers was designed based on the internal transcribed spacer (ITS) region of the rRNA gene of T.marneffei.

Results: The results of the T.marneffei-LAMP were visually reported by the biosensor within 2 min. A range of pathogenic organisms, including various fungus species, as well as several Gram-negative and Gram-positive bacterial species and viruses, were used to determine the analytical sensitivity and specificity of the assay. The optimal reaction condition for the T.marneffei-LAMP-LFB assay was 67 °C within 40 min. The T.marneffei-LAMP-LFB was able to detect up to 400 ag per test. No cross-reactions to non-T.marneffei strains were obtained. The entire procedure, including sample processing (15 min), LAMP reaction (40 min), and result reporting (within 2 min), could be completed within 60 min. Among 120 whole blood samples tested, 25 (20.83%) were T.marneffei-positive by T.marneffei-LAMP-LFB, with a diagnostic accuracy of 100% when compared to fungal culture assay.

Conclusion: The T.marneffei-LAMP-LFB assay targeting the ITS region of the rRNA gene is a rapid, highly sensitive, specific, and straightforward diagnostic tool that may be suitable for use in point-of-care settings and basic medical facilities, especially in rural areas.

Introduction

Talaromyces marneffei (T.marneffei) is a dimorphic fungus commonly found in patients with HIV-infected and immunocompromised (Tsang et al., 2019; Sun et al., 2021). T.marneffei occurs primarily in Southeast Asia, including Thailand, Vietnam, India, Laos, Malaysia, and China’s Guangxi, Guangdong, and other regions (Morris et al., 2024). In recent years, cases of T.marneffei infection have also been reported in non-endemic areas (Patassi et al., 2013; Narayanasamy et al., 2021). The exact route of transmission of T.marneffei is unknown, but inhalation of fungal spores through the respiratory tract is believed to be the most common mode of infection (Pruksaphon et al., 2022). Common manifestations of disseminated T.marneffei infection include recurrent fever, anemia, weight loss, skin lesions, hepatosplenomegaly, lymphadenopathy, and gastrointestinal and respiratory symptoms. Once T.marneffei infection becomes systematic, it can progress rapidly and may be life-threatening without timely and effective antifungal treatment (Liu et al., 2021). Consequently, rapid and accurate identification of T.marneffei at an early stage is crucial for effective disease prevention and control.

Traditional diagnostic methods for T.marneffei infection rely on culture or microscopy, which are time-consuming and have relatively low positive detection rates; however, these methods are still widely used in most laboratories (Tam et al., 2015). Consequently, additional time and effort are required for culture and identification in clinical settings. To enable early, rapid, and accurate identification of T.marneffei, rapid, more efficient, sensitive, and specific diagnostic methods need to be established.

Recently, developing loop-mediated isothermal amplification (LAMP) has significantly improved the detection of pathogenic microorganisms (Jiang et al., 2019; Li et al., 2023; Zhou et al., 2024). It has been successfully employed to detect various bacteria, fungi, viruses, parasites, and other pathogens due to its high specificity, rapidity, and simplicity (Pu et al., 2022; Phurijaruyangkun et al., 2024; Ahmadi et al., 2025). However, traditional methods for verifying LAMP amplification products, including hydroxy naphthol blue (HNB), SYBR Green, and agarose gel electrophoresis (Yang et al., 2024), struggle to distinguish specific amplification from nonspecific amplification, which can lead to misunderstanding of the results. To address these limitations, a visual, sensitive, and target-specific lateral flow biosensor (LFB) can be used to verify nucleic acid-labeled amplification products (Wang et al., 2022; Zhu et al., 2025). This method effectively overcomes the shortcomings of other LAMP amplification product verification methods, such as agarose gel electrophoresis, real-time turbidimetry, and visual indicators, and shortens the verification program time (1–2 min).

The study aimed to develop a rapid and visual detection assay for T.marneffei using LAMP coupled with LFB based on the target sequence and to validate its potential application in clinical samples.

Materials and methods

Reagents and apparatus

Nucleic acid extraction kits for pathogens’ genomic DNA (Beijing Baitaike Biotech Co., Ltd., Beijing, China) and viral RNA (Tianlong Technology Co., Ltd., Xian, China) were commercially obtained. Isothermal amplification kits (RNA/DNA Universal) and visual detection reagents (VDR) were obtained from HUIDEXIN Biotech Co., Ltd. (Tianjin, China). The schematic design of gold nanoparticle-based LFB is shown in Figure 1. Briefly, the LFB consisted of four sections, namely, sample pad, conjugate pad, NC membrane with immobilized anti-FAM and biotin-BSA, and an absorbent pad, all of them were assembled on a plastic adhesive backing card (HuiDeXin Bio-technology, Tianjin, China). Dye coated gold nanoparticles (GNPs) were deposited on the conjugate pad, the size of GNPs was 35 ± 5 nm, and the concentration was 10 mg/mL. Rabbit anti-FAM antibody (0.2 mg/mL; Abcam) and biotin-BSA (4 mg/mL; Abcam) were fixed onto the NC membrane as test line (TL) and control line (CL), respectively. Each line was separated by 5 mm. The purity and concentration of the extracted nucleic acid were analyzed using a Nanodrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) by measuring the A260/A280 ratio.

Figure 1

Figure 1. Schematic diagram of detection workflow of the Talaromyces marneffei-LAMP-LFB assay. (A) The Talaromyces marneffei-LAMP-LFB reaction system with premixed Talaromyces marneffei templates and isothermal reagents was incubated at 63 °C for 60 min and then terminated at 80 °C for 2 min and validation of Talaromyces marneffei-LAMP-LFB amplicons mediated by LFB biosensor. (B) Talaromyces marneffei-LAMP products (1.0 μL) and running buffer (100 μL) were simultaneously added to the sample pad. (C) The running buffer and Talaromyces marneffei-LAMP products move forward to conjugate pad and reaction region due to capillary action. (D) For positive results, the FAM/biotin-labeled LAMP products are arrested by anti-FAM at TL strip, and the streptavidin-GNPs are arrested through Biotin-BSA at CL strip. For negative results, only the streptavidin-GNPs flow to reaction region and arrested by Biotin-BSA at CL strip. (E) Interpretation of the Talaromyces marneffei-LAMP-LFB assay results: negative-only the CL appears on the LFB; positive-CL and TL appear on biosensor. LAMP, loop-mediated isothermal amplification; LFB, nanoparticle-based lateral biosensor; TL, test line; CL, control line.

Pathogenic bacteria and clinical samples

In this study, experimental bacteria, including 16 T.marneffei and 31 non-T.marneffei-isolated strains were used in Table 1. The genomic DNA templates were extracted using a DNA isolation kit (Bio TeKe, Beijing) according to the manufacturer’s instructions. Additionally, 120 clinical samples were collected from patients suspected of having T.marneffei infection who were admitted to the First People’s Hospital of Guiyang. To evaluate the clinical performance of T.marneffei-LAMP-LFB, all clinical samples were tested in parallel using both fungal culture and the T.marneffei-LAMP-LFB method. This study was approved by the ethics committee of the First People’s Hospital of Guiyang (Ethical approval No. G2024-S022). The extracted DNA was stored at −20 °C until use.

Table 1

Table 1. Pathogens used in the current study.

Design of Talaromyces marneffei-LAMP-LFB primers

A set of six primers, including two inner primers (FIP and BIP), two outer primers (F3 and B3), and two loop primers (LF and LB), were designed based on the reaction mechanism of LAMP to target the sequence of the internal transcribed spacer (ITS) region of the rRNA gene (Genbank accession No. AB353913.1). All primers were designed using Primer Explorer V5 (https://primer-explorer.jp/e/; Eiken Chemical Co., Ltd., Tokyo, Japan) and validated using the basic local alignment search tool (Wang et al., 2017). Figure 2 displays primer positions, while Table 2 depicts the primer sequences and modifications. All primers used in this study were synthesized by Beijing-Tsingke Biotechnology Co., Ltd. (Beijing, China) and were of HPLC purification grade.

Figure 2

Figure 2. Appropriate primer design for Talaromyces marneffei-LAMP-LFB assay. The nucleotide sequences of the sense strand of the ITS region of the rRNA gene are listed. Right arrows and left arrows indicate sense and complementary sequences that are used.

Table 2

Table 2. The primers used in the current study.

The standard LAMP assay

The T.marneffei-LAMP-LFB amplification was conducted using a one-step, 25 μL reaction mixture containing the following components of 12.5 μL of 2 × reaction buffer, 1 μL of 2.0 Bst DNA polymerase, 1.6 μM each of FIP and BIP, 0.8 μM each of LF and LB, 0.4 μM each of F3 and B3, 1 μL of VDR indicator, 1 μL of biotin-14-dCTP, 1 μL of DNA template, and double distilled water (DW) was added to reach a final volume of 25 μL. The reaction tubes were incubated at 63 °C for 60 min, followed by enzyme inactivation at 80 °C for 2 min. The details of the standard LAMP reaction flow chart are depicted in Figure 1.

Talaromyces marneffei-LAMP-LFB product detection

Three methods were employed to detect and verify the products of the T.marneffei-LAMP-LFB: real-time turbidity using the LA-500 (Eiken Chemical Co., Ltd., Japan), colorimetric indicators VDR and LFB. In the real-time turbidity method, a turbidity value greater than 0.1 was considered positive. The VDR method visually distinguished positive reactions by a color change from colorless to light green, while negative and blank control remained colorless. Finally, the LFB assay displayed positive results when both the control line (CL) and test line (TL) appeared simultaneously. Conversely, negative amplifications only indicated the CL.

Optimization reaction temperature of the Talaromyces marneffei-LAMP-LFB

To optimize amplification efficiency, the reaction temperature of the T.marneffei-LAMP-LFB assay was evaluated across a temperature range of 61–68 °C in 1 °C increments. Amplification mixtures containing 1 μL DNA of Candida albicans served as negative control, while 1 μL of DW was a blank control. The assay was performed according to the standard LAMP assay, and amplification products from the T.marneffei-LAMP-LFB assay were monitored using the Real-time Turbidimeter LA-500.

Sensitivity and optimal isothermal amplification time of the Talaromyces marneffei-LAMP-LFB assay

Genomic DNA templates from pure culture of T.marneffei were serially diluted 10-fold from 4 ng to 4 ag to confirm the limit of detection (LoD) and evaluate the analytical sensitivity of the LAMP-LFB assay. The LAMP-LFB reactions were conducted under the standard conditions described above, and the results were examined using a VDR and LFB. The LoD of the LAMP-LFB assay was verified as the last dilution of each positive test. Each dilution was tested at least three times to ensure reproducibility.

Additionally, the optimal reaction time for the T.marneffei-LAMP-LFB assay was determined by comparing four different incubation times (20, 30, 40, and 50 min). Amplification products generated at each time point were assessed using both LFB and VDR. Each reaction time was tested in triplicate to ensure consistency. In the experiments, 1 μL of DW was used as a blank control.

Specificity of the Talaromyces marneffei-LAMP-LFB assay

To evaluate the specificity of the T.marneffei-LAMP-LFB assay, the genomic DNA including 16 T.marneffei and 31 non-T.marneffei isolated strains were tested under the optimal amplification temperature and time conditions (Table 1). Amplification products from all samples were monitored using LFB.

Applicability of the Talaromyces marneffei-LAMP-LFB assay to clinical samples

To assess the feasibility of applying the T.marneffei-LAMP-LFB assay for clinical diagnostics, 120 blood samples were collected from patients suspected of T.marneffei infection at the First People’s Hospital of Guiyang. All blood samples were evaluated using both the T.marneffei-LAMP-LFB assay and the traditional clinical cultural-based. Routine laboratory diagnosis of T.marneffei included fungal culture and Gram staining. The T.marneffei-LAMP-LFB detection was performed as previously described. Online statistical software MedCalc (http://www.medcalc.org/calc/diagnostic_test.php) (Version 23.0.5) was used to analyze the traditional clinical cultural-based and T.marneffei-LAMP-LFB assay.

Results

Confirmation of Talaromyces marneffei-LAMP-LFB assay products

To assess the specificity and feasibility of the T.marneffei LAMP primers (Table 2), T.marneffei LAMP reactions were performed at a constant temperature at 63 °C for 60 min using T.marneffei DNA as the template. Amplification products were then visualized using three methods: VDR (Figure 3A), agarose gel electrophoresis (Figure 3B; Supplementary Figure S1) and LFB (Figure 3C). As illustrated in Figure 3, positive results were obtained only with T.marneffei nucleic acid, while no amplification was observed with Candida albicans, Haemophilus influenzae, or the blank control. These results demonstrate the validity of the T.marneffei-LAMP-LFB primers for the ITS region of the rRNA gene detection and their suitability for establishing the T.marneffei-LAMP-LFB assay.

Figure 3

Figure 3. Identification and confirmation of Talaromyces marneffei-LAMP-LFB products. (A) The visible color changes of amplification products of Talaromyces marneffei-LAMP-LFB assay were analyzed by VDR Tube 1, positive amplification; tube 2, negative control DNA of Candida albicans; tube 3, negative control DNA of Haemophilus influenzae; tube 4, blank control (double-distilled water, DW). (B) Agarose gel electrophoresis applied to detecting Talaromyces marneffei-LAMP-LFB products. Lane BM, DL 1,000bp DNA markers, lane B1, positive amplification; lane B2, negative control DNA of Candida albicans; lane B3, negative control DNA of Haemophilus influenzae; lane B4, blank control (double-distilled water, DW). (C) The products of Talaromyces marneffei-LAMP-LFB were visually detected with lateral flow biosensor. Biosensor 1, positive amplification; Biosensor 2, negative control DNA of Candida albicans; Biosensor 3, negative control DNA of Haemophilus influenzae; Biosensor 4, blank control (double-distilled water, DW).

The optimal amplification temperature for the Talaromyces marneffei-LAMP-LFB assay

To achieve better amplification efficiency, the reaction temperature of the LAMP-LFB assays was optimized under standard conditions, and different incubation temperatures ranging from 61–68 °C with an interval of 1 °C were used for the LAMP assays. Real-time turbidity was monitored using an LA-500 instrument. Based on the results presented in Figure 4, 67 °C was identified as the optimal reaction temperature for T.marneffei-LAMP-LFB amplification. This conclusion is supported by the observation that the threshold value of 0.1 absorbance, indicative of positive amplification, was achieved most rapidly at 67 °C. Consequently, 67 °C was used for all subsequent T.marneffei-LAMP-LFB reactions in this study.

Figure 4

Figure 4. Optimal amplification temperature for Talaromyces marneffei-LAMP-LFB assay. By using a real-time measurement to monitor the turbidity of Talaromyces marneffei-LAMP-LFB reactions. The corresponding curves were displayed in the panels. Eight kinetic graphs (A–H) were generated at various temperatures (61–68 °C, 1 °C intervals) with target pathogens DNA at the level of 10 pg. per tube (The threshold value was 0.1 and the turbidity of >0.1 was considered to be positive). The graphs from B (62 °C) to H (68 °C) showed robust reaction. The optimal amplification temperature was 67 °C.

Sensitivity and optimized time of the Talaromyces marneffei-LAMP-LFB assay

Using the LAMP-LFB method, the sensitivity of the T.marneffei-LAMP-LFB assay was tested through serial dilutions of extracted DNA. The final concentrations of the DNA templates were 4 ng, 400 pg., 40 pg., 4 pg., 400 fg, 40 fg, 4 fg, 400 ag, 40 ag, and 4 ag per reaction mixture. As presented in Figure 5, when the dilution exceeded 400 ag, the LAMP tubes were colorless and only displayed the control band on the LFB.

Figure 5

Figure 5. Sensitivity analysis of the Talaromyces marneffei-LAMP-LFB assays with serial dilutions of Talaromyces marneffei genomic DNA concentrations. Two measurement techniques, including (A) A colorimetric indicator (VDR) and (B) Lateral flow biosensor. A series of dilutions from 4 ng to 4 ag per microliter DNA and a blank control double-distilled water were operated according to standard LAMP-LFB reactions.

To determine the optimal amplification time for the T.marneffei-LAMP-LFB assay, four different incubation times (20, 30, 40, and 50 min) were evaluated at 67 °C. The amplified products were subsequently analyzed using LFB. The results confirmed that the LoD level of DNA (400 ag per reaction) was tested when the amplification lasted 40 min (Figure 6). Consequently, an amplification temperature of 67 °C and a duration of 40 min were selected as the optimal conditions for subsequent T.marneffei-LAMP-LFB assays in this study.

Figure 6

Figure 6. Optimal detection time required for Talaromyces marneffei-LAMP-LFB assay. Four different reaction times [(A) 20 min; (B) 30 min; (C) 40 min; (D) 50min] were evaluated at 67 °C. Biosensors 1–7 represent Talaromyces marneffei DNA levels of 40 pg. to 40 ag copies per reaction, respectively; 8 represents a blank control double-distilled water.

Specificity of the Talaromyces marneffei-LAMP-LFB assay

The specificity of the T.marneffei-LAMP-LFB assay was evaluated using a panel of 16 isolated T.marneffei strains and 31 non-T.marneffei pathogens, as detailed in Table 1. The T.marneffei-LAMP-LFB detection assays were performed under the previously established optimal conditions (67 °C and 40 min incubation). As illustrated in Figure 7, samples containing T.marneffei exhibited a color change from colorless to light green and produced two distinct red lines at both the TL and CL positions on the LFB strip, while all non-T.marneffei pathogens and the blank control remained colorless and indicated only a single red line at the CL position. These results confirm that the T.marneffei-LAMP-LFB assay can accurately differentiate T.marneffei from other microbes.

Figure 7

Figure 7. Specificity of LFB assays detecting Talaromyces marneffei-LAMP-LFB products. (A) The visible color changes of amplification products of Talaromyces marneffei-LAMP-LFB assay were analyzed by VDR. (B) The products of Talaromyces marneffei-LAMP-LFB were visually detected with LFB. The VDR visually distinguished positive reactions by a color change from colorless to light green, while negative and blank control remained colorless. Both the control line and the test line were visible in LFB for all Talaromyces marneffei, and only the control line was appeared in non-Talaromyces marneffei. 1–16, Talaromyces marneffei isolated strains; 17, Staphylococcus aureus isolated strains; 18, Klebsiella pneumoniae isolated strains; 19–22, Haemophilus influenzae isolated strains; 23–26, Enterococcus faecalis isolated strains; 27, Escherichia coli isolated strains; 28–33, Candida albicans isolated strains; 34–36, Candida tropicalis isolated strains; 37–39, Candida glabrata isolated strains; 40, Candida parapsilosis isolated strains; 41, Meyerozyma guilliermondii isolated strains; 42, Pichia kudriavzevii isolated strains; 43, Aspergillus flavus Aspergillus flavus; 44, Listeria monocytogenes isolated strains; 45, Norovirus clinical samples; 46, EVA71 isolated strains; 47, CVA16 isolated strains; 48, a blank control double distilled water (DW).

Application of LAMP-LFB to Talaromyces marneffei clinical samples

To assess the clinical applicability of the T.marneffei-LAMP-LFB assay, 120 clinical blood samples from patients suspected of T.marneffei were simultaneously tested using both the T.marneffei-LAMP-LFB and a traditional fungal culture method. Compared with traditional fungal culture assay, our assay’s sensitivity and specificity were 100% [95% confidence interval (CI): 86.28–100.00%] and 100% (95% CI: 96.19–100.00%), respectively (Table 3).

Table 3

Table 3. Comparison of culture and Talaromyces marneffei-LAMP-LFB methods to identify Talaromyces marneffei in clinical samples.

Discussion

T.marneffei is the only temperature-bidirectional fungus in the Penicillium genus and is the causative agent of disseminated and progressive infection in humans, primarily in Southeast Asian countries and southern China (Wang et al., 2023). Approximately 17,300 cases of T.marneffei infection are diagnosed each year, with a reported mortality rate of extremely high (~1/3) (Wang et al., 2023). In recent years, with the increasing incidence of HIV, the widespread use of organ transplantation and various catheter interventions, and the extensive use of broad-spectrum antibiotics, adrenocortical hormones, and immunosuppressants, the immunity of many patients has been deficient or declining. The incidence of T.marneffei infection has increased significantly, and the epidemic area has been continuously expanding (Casalini et al., 2024). Patients infected with T.marneffei are often misdiagnosed with other infections, particularly tuberculosis or bacterial pneumonia, due to overlapping clinical features and similar pulmonary imaging findings (Harika et al., 2024).

Currently, delayed diagnosis is the primary cause of a high mortality rate in patients co-infected with HIV or infected with T.marneffei (Ye et al., 2024). T.marneffei is typically diagnosed through microscopic identification and culture techniques of the fungal culture in clinical samples. Due to its unique morphological and dimorphic characteristics, T.marneffei grows as a mycelium at 25 °C and as yeast at 37 °C (Cao et al., 2007). However, traditional detection methods (microbial culture, histopathological examination, and serological determination) usually cannot meet the requirements for rapid detection in terms of time and sensitivity.

Consequently, there is a critical need for rapid, accurate, and sensitive diagnostic tools or kits to facilitate prompt clinical intervention and effective disease control. Molecular biology methods and techniques have significantly improved the early and rapid diagnosis of infectious diseases. Over the years, several nucleic acid-based assays have been developed for T.marneffei detection (nested or semi-nested PCR, PCR enzyme immunoassays, and PCR hybridization); however, these methods are often limited by their high cost, routine operation, and applicability in laboratories lacking specialized equipment (Liu et al., 2016; Lu et al., 2016). Among the various rapid testing methods, LAMP is an innovative gene amplification method that provides a rapid and straightforward tool for the early detection and identification of microbial pathogens. It has been widely used for the detection of various pathogens, including viruses, bacteria, and fungi (Notomi et al., 2015). However, the validation and analysis of LAMP products, including VDR, agarose gel electrophoresis, and real-time turbidimetry, remains a key challenge.

The LFB was designed and developed to validate LAMP amplification products by labeling special primers, and it is widely used in the analysis of LAMP products (Chen et al., 2021; Jiang et al., 2021). During operation, only (1.0 μL) of the LAMP amplicon and the same (100 μL) of the running buffer were added to the sample pad, and the results were verified by observing the color changes in TL and/or CL with the naked eye. Using LFB (1–2 min) greatly reduces the analysis time of LAMP products. Compared with other methods (colorimetric index, agarose gel electrophoresis, real-time turbidity), the LFB method is not only fast and sensitive but also a user-friendly, and error-tolerant approach, especially in terms of reducing the need for special instruments, reagents, and other verification steps.

In the present study, a set of primers was designed based on the ITS region of the rRNA gene of T.marneffei, and the gene was amplified via an isothermal amplification device. The clinical effectiveness of ITS targets has been confirmed in multiple diagnostic studies, especially suitable for the early detection of yeast-like infections, providing a basis for the recognition of T. marneffei (Liu et al., 2016; Lu et al., 2016; Wang et al., 2025). To determine the best reaction conditions, we used different reaction temperatures and reaction times in the LAMP-LFB assay. The amplification efficiency of LAMP-LFB at 67 °C was greater than that at other temperatures (Figure 4). Additionally, T.marneffei-LAMP-LFB has high sensitivity, and the results revealed that the LoD level of the genomic DNA 400 ag per microliters could be detected after 40 min of amplification (Figures 5, 6). It has a higher sensitivity than currently applied molecular methods, which are 10–100 times greater than those of nested PCR and real-time PCR (Liu et al., 2016; Lu et al., 2016). In addition to the high sensitivity and high specificity of the T.marneffei-LAMP-LFB assay, only T.marneffei samples were detected, while other species were undetected (Figure 7). To verify its practicality, a comparative method was used to detect T.marneffei-LAMP-LFB in 120 clinical blood samples, and the results also revealed that T.marneffei-LAMP-LFB was less time-consuming, consistent with the results of traditional fungal culture methods (Table 3).

A limitation of our study is that we only tested the assay on patient blood samples. The clinical diversity of T.marneffei infection can include damage to the skin, mouth, lungs, digestive tract, bone, and other systems, and our method of examination also requires different types of clinical samples. Although there are limitations, further research is needed to validate its clinical application, and the apparent advantage of this method lies in its speed and high specificity. In this experiment, LFB is more convenient, accurate and operable regarding instrument requirements. As T.marneffei-LAMP-LFB only requires incubation at an isothermal temperature of 67 °C for 40 min and does not require sophisticated instrumentation, many thermostatically controlled instruments can be used for amplification procedures (constant-temperature water baths), making it particularly suitable for care sites and field laboratories.

Conclusion

In conclusion, we developed a novel method (T.marneffei-LAMP-LFB) for timely, portably and accurately diagnosis of T.marneffei infection. The T.marneffei-LAMP-LFB method could intuitively reflect the detection result and eliminate the need for complex procedures and costly instrumentation. In the process of application and evaluation, the T.marneffei-LAMP-LFB method indicated good specificity and sensitivity for detecting T.marneffei samples within 1h with simple thermostatic instruments. It can be considered a potential screening tool for T.marneffei infection in clinical, basic, field, and resource-poor areas.

Data availability statement

The datasets presented in this article are not readily available because the original contributions presented in the study are included in the article/Supplementary material. Further inquiries can be directed to the corresponding author. Requests to access the datasets should be directed to d2FuZ3pob25neXV3eUAxNjMuY29t.

Ethics statement

The studies involving humans were approved by the Ethics Committee of the First People’s Hospital of Guiyang (Ethical approval No. G2024-S022) and acts following the Declaration of Helsinki. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.

Author contributions

YZ: Conceptualization, Methodology, Writing – original draft, Software, Data curation, Formal analysis. RY: Writing – review & editing, Formal analysis, Data curation, Visualization, Methodology. YiW: Data curation, Methodology, Writing – review & editing. XZ: Writing – review & editing, Formal analysis, Data curation, Methodology. HY: Writing – review & editing, Resources, Funding acquisition. YuW: Writing – review & editing, Validation, Funding acquisition, Resources, Project administration, Writing – original draft, Conceptualization.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the grant of the Science and Technology Department of Guizhou Province [Qian Ke He Zhi Cheng (2021) Yi Ban 440]. Zhu Ke He Tong (2020)-10–6, Zhu Ke He Tong (2021)-43–25, GCC (2023)030 and (2024) Zhu Wei Jian Ke Ji He Tong Zi Di 005, from the Science and Technology Department of Guiyang City of Guizhou Province.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The authors declare that no Gen AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2025.1661312/full#supplementary-material

References

Ahmadi, Y., Yu, Y., Cui, Z., Huang, W. E., and Andersson, M. I. (2025). Loop-mediated isothermal amplification (LAMP) for the diagnosis of sexually transmitted infections: a review. Microb. Biotechnol. 18:e70153. doi: 10.1111/1751-7915.70153

PubMed Abstract | Crossref Full Text | Google Scholar

Cao, C., Li, R., Wan, Z., Liu, W., Wang, X., Qiao, J., et al. (2007). The effects of temperature, pH, and salinity on the growth and dimorphism of Penicillium marneffei. Med. Mycol. 45, 401–407. doi: 10.1080/13693780701358600

PubMed Abstract | Crossref Full Text | Google Scholar

Casalini, G., Giacomelli, A., and Antinori, S. (2024). The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation. Lancet Microbe 5, 717–724. doi: 10.1016/s2666-5247(24)00042-9

PubMed Abstract | Crossref Full Text | Google Scholar

Chen, C., Lu, J., Long, B., Rao, Z., Gao, Y., Wang, W., et al. (2021). Detection of Mycobacterium kansasii using a combination of loop-mediated isothermal amplification (LAMP) and lateral flow biosensors. Int. Microbiol. 24, 75–82. doi: 10.1007/s10123-020-00143-z

PubMed Abstract | Crossref Full Text | Google Scholar

Harika, P., Asthana, B., Vashisht, R., Yadav, N., Hazra, N., Manrai, M., et al. (2024). Disseminated talaromycosis: truly uncommon or uncommonly recognized? Med. J. Armed Forces India 80, S247–s251. doi: 10.1016/j.mjafi.2022.12.008

PubMed Abstract | Crossref Full Text | Google Scholar

Jiang, L., Gu, R., Li, X., and Mu, D. (2021). Simple and rapid detection aspergillus fumigatus by loop-mediated isothermal amplification coupled with lateral flow biosensor assay. J. Appl. Microbiol. 131, 2351–2360. doi: 10.1111/jam.15092

PubMed Abstract | Crossref Full Text | Google Scholar

Jiang, J., Meng, S., Huang, S., Ruan, Y., Lu, X., Li, J. Z., et al. (2019). Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: a retrospective cohort study. Clin. Microbiol. Infect. 25, 233–241. doi: 10.1016/j.cmi.2018.04.018

PubMed Abstract | Crossref Full Text | Google Scholar

Li, M., Jin, X., Jiang, Q., Wei, H., Deng, A., Mao, Z., et al. (2023). Loop-mediated isothermal amplification (LAMP): potential point-of-care testing for vulvovaginal candidiasis. J Fungi 9:1159. doi: 10.3390/jof9121159

PubMed Abstract | Crossref Full Text | Google Scholar

Liu, Y., Huang, X., Yi, X., He, Y., Mylonakis, E., and Xi, L. (2016). Detection of Talaromyces marneffei from fresh tissue of an inhalational murine pulmonary model using nested PCR. PLoS One 11:e0149634. doi: 10.1371/journal.pone.0149634

PubMed Abstract | Crossref Full Text | Google Scholar

Liu, W., Xu, J., Lin, B., Zhang, Y., Xie, F., Zhou, C., et al. (2021). Pneumonia caused by Talaromyces marneffei in an epidermal growth factor receptor (EGFR) mutation-positive advanced lung adenocarcinoma patient: a case report. Ann. Palliat. Med. 10, 759–766. doi: 10.21037/apm-20-2137

PubMed Abstract | Crossref Full Text | Google Scholar

Lu, S., Li, X., Calderone, R., Zhang, J., Ma, J., Cai, W., et al. (2016). Whole blood nested PCR and real-time PCR amplification of Talaromyces marneffei specific DNA for diagnosis. Med. Mycol. 54, 162–168. doi: 10.1093/mmy/myv068

PubMed Abstract | Crossref Full Text | Google Scholar

Morris, A. J., Kim, H. Y., Nield, B., Dao, A., Mcmullan, B., Alastruey-Izquierdo, A., et al. (2024). Talaromyces marneffei, coccidioides species, and paracoccidioides species-a systematic review to inform the world health organization priority list of fungal pathogens. Med. Mycol. 62:myad133. doi: 10.1093/mmy/myad133

PubMed Abstract | Crossref Full Text | Google Scholar

Narayanasamy, S., Dat, V. Q., Thanh, N. T., Ly, V. T., Chan, J. F., Yuen, K. Y., et al. (2021). A global call for talaromycosis to be recognised as a neglected tropical disease. Lancet Glob. Health 9, e1618–e1622. doi: 10.1016/s2214-109x(21)00350-8

PubMed Abstract | Crossref Full Text | Google Scholar

Notomi, T., Mori, Y., Tomita, N., and Kanda, H. (2015). Loop-mediated isothermal amplification (LAMP): principle, features, and future prospects. J. Microbiol. 53, 1–5. doi: 10.1007/s12275-015-4656-9

PubMed Abstract | Crossref Full Text | Google Scholar

Patassi, A. A., Saka, B., Landoh, D. E., Kotosso, A., Mawu, K., Halatoko, W. A., et al. (2013). First observation in a non-endemic country (Togo) of Penicillium marneffei infection in a human immunodeficiency virus-infected patient: a case report. BMC. Res. Notes 6:506. doi: 10.1186/1756-0500-6-506

PubMed Abstract | Crossref Full Text | Google Scholar

Phurijaruyangkun, S., Tangjitrungrot, P., Jaratsing, P., Augkarawaritsawong, S., Kumkrong, K., Pongparit, S., et al. (2024). A loop-mediatedisothermal amplification assay utilizing hydroxy naphthol blue (LAMP-HNB) for the detection of Treponema pallidum subspp. pallidum. Pathogens 13:949. doi: 10.3390/pathogens13110949

PubMed Abstract | Crossref Full Text | Google Scholar

Pruksaphon, K., Nosanchuk, J. D., Ratanabanangkoon, K., and Youngchim, S. (2022). Talaromyces marneffei infection: virulence, intracellular lifestyle and host defense mechanisms. J Fungi 8:200. doi: 10.3390/jof8020200

PubMed Abstract | Crossref Full Text | Google Scholar

Pu, R., Liu, S., Ren, X., Shi, D., Ba, Y., Huo, Y., et al. (2022). The screening value of RT-LAMP and RT-PCR in the diagnosis of COVID-19: systematic review and meta-analysis. J. Virol. Methods 300:114392. doi: 10.1016/j.jviromet.2021.114392

PubMed Abstract | Crossref Full Text | Google Scholar

Sun, J., Sun, W., Tang, Y., Zhang, R., Liu, L., Shen, Y., et al. (2021). Clinical characteristics and risk factors for poor prognosis among HIV patients with Talaromyces marneffei bloodstream infection. BMC Infect. Dis. 21:514. doi: 10.1186/s12879-021-06232-2

PubMed Abstract | Crossref Full Text | Google Scholar

Tam, E. W., Tsang, C. C., Lau, S. K., and Woo, P. C. (2015). Polyketides, toxins and pigments in Penicillium marneffei. Toxins 7, 4421–4436. doi: 10.3390/toxins7114421

PubMed Abstract | Crossref Full Text | Google Scholar

Tsang, C. C., Lau, S. K. P., and Woo, P. C. Y. (2019). Sixty years from segretain's description: what have we learned and should learn about the basic mycology of Talaromyces marneffei? Mycopathologia 184, 721–729. doi: 10.1007/s11046-019-00395-y

PubMed Abstract | Crossref Full Text | Google Scholar

Wang, F., Han, R., and Chen, S. (2023). An overlooked and underrated endemic mycosis-talaromycosis and the pathogenic fungus Talaromyces marneffei. Clin. Microbiol. Rev. 36:e0005122. doi: 10.1128/cmr.00051-22

PubMed Abstract | Crossref Full Text | Google Scholar

Wang, Y., Li, H., Wang, Y., Zhang, L., Xu, J., and Ye, C. (2017). Loop-mediated isothermal amplification label-based gold nanoparticles lateral flow biosensor for detection of enterococcus faecalis and Staphylococcus aureus. Front. Microbiol. 8:192. doi: 10.3389/fmicb.2017.00192

PubMed Abstract | Crossref Full Text | Google Scholar

Wang, Y., Wang, X., Xi, L., and Lu, S. (2025). Advancements in diagnosing Talaromycosis: exploring novel strategies and emerging technologies. J Fungi 11:434. doi: 10.3390/jof11060434

PubMed Abstract | Crossref Full Text | Google Scholar

Wang, Y., Zhao, X., Zhou, Y., Lu, J., Yu, H., and Li, S. (2022). Establishment and application of loop-mediated isothermal amplification coupled with nanoparticle-based lateral flow biosensor (LAMP-LFB) for visual and rapid diagnosis of Candida albicans in clinical samples. Front. Bioeng. Biotechnol. 10:1025083. doi: 10.3389/fbioe.2022.1025083

PubMed Abstract | Crossref Full Text | Google Scholar

Yang, N., Zhang, H., Han, X., Liu, Z., and Lu, Y. (2024). Advancements and applications of loop-mediated isothermal amplification technology: a comprehensive overview. Front. Microbiol. 15:1406632. doi: 10.3389/fmicb.2024.1406632

PubMed Abstract | Crossref Full Text | Google Scholar

Ye, L. Y., Zhao, X. L., Qin, J. J., and Lin, J. (2024). Metagenomic next-generation sequencing assisted in the successful treatment of pneumonia caused by Talaromyces marneffei in an immunocompetent patient. J. Infect. Dev. Ctries. 18, 1296–1300. doi: 10.3855/jidc.19061

PubMed Abstract | Crossref Full Text | Google Scholar

Zhou, S., Yang, Z., Guo, B., Yi, J., Pang, Y., Feng, R., et al. (2024). Rapid visual detection of Spiroplasma eriocheiris by loop-mediated isothermal amplification with hydroxynaphthol blue dye. Mar. Biotechnol. (N.Y.) 26, 116–124. doi: 10.1007/s10126-023-10282-9

PubMed Abstract | Crossref Full Text | Google Scholar

Zhu, H., Zhao, S., Luo, J., Obaid, M. K., Zhang, S., Liu, P., et al. (2025). Differential detection of ovine Theileria species using loop-mediated isothermal amplification combined with nanoparticle-based lateral flow biosensor. Vet. Parasitol. 336:110443. doi: 10.1016/j.vetpar.2025.110443

PubMed Abstract | Crossref Full Text | Google Scholar